EOS imaging obtains regulatory authorization to sell its products in Taiwan

  EOS imaging obtains regulatory authorization to sell its products in Taiwan

EOS® can now be deployed in Taiwan, further advancing the Company’s expansion
                         into the Asia-Pacific region

Business Wire

PARIS -- April 14, 2014

Regulatory News:

EOS imaging (Paris:EOSI) (Euronext, FR0011191766-EOSI), the pioneer in
orthopaedic 2D/3D imaging, eligible for PEA-PME, today announced that
Taiwanese regulatory authorities have authorized the sale of the EOS® imaging
system. The EOS imaging system offers ultra-low radiation dose 2D and 3D X-ray
imaging of the full body in a natural weight-bearing position. It has already
been approved for sale in more than 30 countries.

Approval from Taiwanese regulators represents an important milestone as the
Company continues its commercial development efforts in the Asia-Pacific
region. EOS has also signed a distribution agreement with the Taiwanese
company Unison Co. Ltd. to sell EOS imaging systems in the country.

Marie Meynadier, CEO of EOS imaging, noted: “the regulatory authorization to
deploy our system in Taiwan reflects the continued momentum of our commercial
development in the Asia-Pacific region. Together with a strong partnership
with our local distributor in Taiwan, this new step now allows us to deploy
EOS in this significant Asian market.”

About EOS imaging:

EOS imaging designs, develops, and markets EOS®, a revolutionary and patented
medical imaging system, based on technology that enabled George Charpak to win
the Nobel Prize for Physics. The Company is authorized to market the system in
32 countries, including the United States (FDA), Japan, Canada, Australia and
the European Union (EU). Backed by an installed base of 75 sites and more than
400,000 imaging sessions, EOS® benefits from worldwide recognition within the
global medical community. AsofDecember31, 2013 the Group posted 2013
consolidated revenue of €15.2 million and employed 101 people including an R&D
team of 38engineers. The Group is based in Paris and holds four subsidiaries
in Besançon (France), Cambridge (Massachusetts), in Montreal (Canada) and
Frankfurt (Germany), and offices in Singapore. For further information, please
visit www.eos-imaging.com

           EOS imaging is listed on Compartment C of Euronext Paris
                      ISIN: FR0011191766 – Ticker: EOSI
Next press release: revenue for the 1^st half of 2014, on July 22, 2014 (after
                                   market).

Contact:

EOS imaging
Anne Renevot, +33 (0)1 55 25 61 24
CFO
investors@eos-imaging.com
or
NewCap.
Financial communication and investor relations
Sophie Boulila / Pierre Laurent, +33 (0)1 44 71 94 91
eosimaging@newcap.fr
or
The Ruth Group (US)
Press relations
Melanie Sollid-Penton, 646-536-7023
msollid@theruthgroup.com
 
Press spacebar to pause and continue. Press esc to stop.